S14 : Symposium14 「Management of Superficial Bladder Cancer」**Introduction**

Department of Urology and Andrology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan¹⁾, Department of Urology Hamamatsu University School of Medicine, Hamamatsu, Japan²⁾

Hideyuki Akaza¹⁾, Seiichiro Ozono²⁾

The majority of patients with bladder cancer present with papillary tumors confined to the urothelium (Ta) or invading to the lamina propria (T1). Transurethral resection of bladder tumor (TURBt) is a usual manner to treat superficial bladder cancer. Intravesical instillations of anti-cancer agents are administered for prophylaxis treatment for tumor recurrence. Despite this preventive therapy, however, the incidence of tumor recurrence within 1 or 2 years after TURBt is as high as 50% or more. Furthermore, recurrent tumors undergo progression in 10-20% of all cases. Professor Seiji Naito, President of the 94th annual meeting of the JUA, planned one symposium entitled, "Management of Superficial Bladder Cancer" and asked us to chair this session as conductors. Therefore, we organized this symposium to discuss strategy and treatment modalities for high risk superficial bladder cancer and invited one special guest from abroad, Dr. Michael A. O' Donnell, University of IOWA, and five of Japanese representative uro-oncologists. As you may know that Dr. O' Donnell has been conducting many investigations on immunotherapy for superficial bladder cancer, first of all, he will present his previous data as a special lecture. After that, natural history of superficial bladder cancer analyzed by hazard smoothing method will be presented by Dr. Shiro Hinotsu, University of Tsukuba, and risk factors and prediction of recurrence will be presented by Dr. Kiyohide Fujimoto, Nara Medical University. As for treatment modalities, intravesical chemotherapy and BCG therapy will be presented by Dr. Tomoyasu Tsushima, Okayama Medical Center and Dr. Soichi Mugiya, Hamamatsu University School of Medicine, respectively. Finally, Dr. Toshiyuki Kamoto, Kyoto University will review the current status of radical cystectomy in patients with high risk noninvasive bladder cancer. Through the symposium, all speakers and we wish to clarify improved prognostic markers and more effective delivery of intravesical agents for future refinements in the treatment of patients with high risk superficial bladder cancer.